Clinical Trial Update: Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II study of Avastin + Erbitux + Irinotecan as second-line treatment for colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Camptosar (irinotecan)
• ERBITUX (cetuximab)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED